Abstract LB-274: Identification and characterization of LY3410738, a novel covalent inhibitor of cancer-associated mutant Isocitrate Dehydrogenase 1 (IDH1)
Nathan A. Brooks(Eli Lilly (United States)), Raymond Gilmour(Eli Lilly (Spain)), Lisa Kays(Eli Lilly (United States)), Zoran Ranković(St. Jude Children's Research Hospital), P.L. Milligan(Eli Lilly (United States)), John Strelow(Eli Lilly (United States)), Stephen Antonysamy(Eli Lilly (United States)), Robin DeWalt(Eli Lilly (United States)), Denis McCann(Eli Lilly (United States)), Rachel N. Cavitt(Eli Lilly (United States)), Serge L. Boulet(Eli Lilly (United States)), Kenneth D. Roth(Eli Lilly (United States)), Gary Mo(Eli Lilly (United States)), Sandaruwan Geeganage(Eli Lilly (United States)), Patric J. Hahn(Eli Lilly (United States)), Ramón V. Tiu(Eli Lilly (United States)), Sandra Milena Gómez(Eli Lilly (United States)), Renato A. Bauer(Eli Lilly (United States)), Timothy P. Burkholder(Eli Lilly (United States)), ZhaoHai Lu(Eli Lilly (United States))
Cited by 11
Related Papers
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190
100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19
|Nature Reviews Urology|2021|154
Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
|Molecular Cancer Therapeutics|2013|121